ArticleCEN case reports2026
Severe growth retardation in Dent disease: a case report of a novel OCRL variant.
Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDent disease type 2 (DD-2) is a rare X-linked recessive renal tubulopathy caused by mutations in the OCRL gene. Clinically it is characterised by low molecular weight proteinuria (LMWP), hypercalciuria, and nephrocalcinosis. The phenotypic spectrum of DD-2 is expanding with the identification of new pathogenic variants. CASE REPORT: A 12-year-old male presenting with marked short stature and poor weight gain was found to have LMWP, haematuria, hypercalciuria, and bilateral nephrocalcinosis on initial clinical evaluation. Renal function was normal. There was no relevant family history. Genetic analysis revealed a hemizygous missense variant (c.899 C > A; p.Ala300Asp) in the OCRL gene, which has not been previously reported in the literature. No abnormalities were found on ocular or neurological examination as the same gene also causes Lowe syndrome. Therefore DD-2 was considered in this patient. Hydrochlorothiazide treatment was initiated but discontinued due to hypokalaemia. Growth hormone therapy was started by the endocrinology clinic due to severe growth retardation.
conclusionDent disease can present with a wide range of clinical findings. This case report describes a novel OCRL gene variant associated with DD-2. This newly identified variant contributes to the genotypic and phenotypic diversity of the disease, however, without functional validation, it is difficult to determine whether growth retardation is a significant complication in DD-2. Early diagnosis and a multidisciplinary approach are crucial for improving long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.